Production (Stage)
Capricor Therapeutics, Inc.
CAPR
$12.19
-$0.19-1.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -242.74% | 43.32% | -14.15% | -12.31% | -1,185.15% |
| Total Depreciation and Amortization | 7.93% | 4.01% | 1.20% | 7.69% | 7.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 145.51% | 17.24% | -4.77% | -34.18% | 75.77% |
| Change in Net Operating Assets | 211.79% | -602.36% | 60.73% | -176.70% | 138.02% |
| Cash from Operations | 56.52% | -27.09% | 5.26% | -868.82% | 89.06% |
| Capital Expenditure | -55.21% | -1,145.25% | 27.07% | 87.82% | 8.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 120.41% | -6,043.06% | -86.03% | 267.19% | -72.16% |
| Cash from Investing | 119.36% | -6,254.92% | -86.36% | 254.65% | -62.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.94% | 20.44% | 3,157.07% | -9.74% | -90.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.94% | 20.44% | 3,157.07% | -9.74% | -90.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 130.67% | -198.96% | 1,189.51% | 152.75% | -248.51% |